CFTR and cystic fibrosis: Ivacaftor (formerly VX-770, Figure 3) was the first CFTR modulator approved by the Food and Drug Administration (FDA) in 2012 with the name of Kalydeco® for the treatment of CF patients heterozygous for the G551D, the most common variant of class III.